Health Economics

Learn about comparative effectiveness research and evidence-based medicine with this easy-to-understand guide, and how these concepts impact various stakeholders in the healthcare sector

Delve into the world of misleading statistics in healthcare and explore the need for accurate data interpretation

Overview of NICE's updated appeals guide

This article provides a brief overview of the updated NICE technology appeals guidance and its importance to developers, manufacturers, health care providers, and patients.

Uncover why Americans consume more medicine than other countries, yet get no healthier

Exploring key learnings and insights on health technology assessment from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting.

An insight into the drug development process and HTA agencies in Europe, as discussed at the ISPOR Annual Conference

Understanding the language of evidence-based health policy: exploring comparative effectiveness research (CER) and health technology assessment (HTA) across several countries

Explore the study on medical bankruptcy in the US and its impact on the ongoing healthcare reform debate

Researchers from the Dartmouth Atlas Project discuss regional variations in Medicare spending and their impact on solvency.

The NICE Citizens Council discusses the cost per QALY threshold and its implications for healthcare resource allocation

Discover useful tips for health economists to communicate complex risk assessments and health-related information in a way that's easy to understand for the general public

A brief overview of Obama's healthcare plan and its potential economic implications, as well as criticisms from health economists.

Dr. Walter Tsou discusses the potential benefits of a universal, government-run health system in the United States, including efficiency and equity

NICE rules 4 kidney cancer drugs not effective enough for NHS coverage, raising concerns about cost-effectiveness and patient access.